Clinicopathological features of gastric de novo diffuse large B-cell lymphoma with and without Helicobacter pylori infection
| Variable | Total n (%) | H. pylori-positive n (%) | H. pylori-negative n (%) | P value | |||
| Total no | 252 | (100) | 128 | (50.8) | 124 | (49.2) | |
| Sex | |||||||
| Female | 130 | (51.6) | 71 | (55.5) | 59 | (47.6) | 0.210 |
| Male | 122 | (48.4) | 57 | (44.5) | 65 | (52.4) | |
| Age (years old) | |||||||
| <60 | 156 | (61.9) | 89 | (69.5) | 67 | (54.0) | 0.011 |
| ≥60 | 96 | (38.1) | 39 | (30.5) | 57 | (46.0) | |
| Endoscopic features | |||||||
| Ulceration or ulcerated mass | 145 | (57.5) | 87 | (68.0) | 58 | (46.8) | 0.001 |
| Non-ulcerative lesions | 107 | (42.5) | 41 | (32.0) | 66 | (53.2) | |
| Location of tumor (s) | |||||||
| Proximal or ≥2 components | 39 | (15.5) | 31 | (24.2) | 8 | (6.5) | 0.000 |
| Distal | 213 | (84.5) | 97 | (75.8) | 116 | (93.5) | |
| Presence of B symptoms | |||||||
| Yes | 69 | (27.4) | 13 | (10.2) | 56 | (45.2) | 0.000 |
| No | 183 | (72.6) | 115 | (89.8) | 68 | (54.8) | |
| Stage | |||||||
| IE* | 150 | (59.5) | 93 | (72.7) | 67 | (54.0) | 0.000 |
| IIE† | 102 | (40.5) | 35 | (27.3) | 57 | (46.0) | |
| ECOG | |||||||
| 0–1 | 214 | (84.9) | 111 | (86.7) | 103 | (83.1) | 0.418 |
| ≥2 | 38 | (15.1) | 17 | (13.3) | 21 | (16.9) | |
| LDH | |||||||
| Normal (＜200) | 182 | (72.2) | 105 | (82.0) | 77 | (62.1) | 0.000 |
| High (≥200) | 70 | (27.8) | 23 | (18.0) | 47 | (37.9) | |
| IPI risk group | |||||||
| Low (intermediate) risk | 124 | (49.2) | 85 | (66.4) | 39 | (31.5) | 0.000 |
| High risk or relapse | 128 | (50.8) | 43 | (33.6) | 85 | (68.5) | |
| HPE or chemotherapy response | |||||||
| pCR | 74 | (29.4) | 50 | (39.1) | 24 | (19.4) | 0.001 |
| PR+SD+PD | 178 | (70.6) | 78 | (60.9) | 100 | (80.6) | |
| Histologic subclassification | |||||||
| GCB | 79 | (31.3) | 50 | (39.1) | 29 | (23.4) | 0.016 |
| Non-GCB | 173 | (68.7) | 78 | (60.9) | 95 | (76.6) | |
| TIL-Ts score | |||||||
| Low TIL-Ts | 89 | (35.3) | 35 | (27.3) | 67 | (54.0) | 0.012 |
| High TIL-Ts | 163 | (64.7) | 93 | (72.7) | 57 | (46.0) | |
| Chemotherapy regimen | |||||||
| Anthracycline based‡ | 52 | (20.6) | 26 | (20.3) | 26 | (20.9) | 0.961 |
| Rituximab/anthracycline based§ | 72 | (28.6) | 40 | (31.3) | 32 | (25.8) | |
| Rituximab/nonanthracycline based¶ | 19 | (7.5) | 9 | (7.0) | 10 | (8.1) | |
| Others** | 109 | (43.3) | 53 | (41.4) | 56 | (45.2) | |
Proximal: Middle body, upper body, fundus or cardia; distal: antrum, angle or lower body. Non-ulcerative lesions: gastritis-like or multiple erosions on infiltrative mucosa, erosions on giant nodular folds or mixed lesions.
The χ2 test was applied to assess the associations between H. pylori infection and clinicopathological parameters. The p values with statistical significance are shown in bold.
*Total, stage IE, 96/55; H. pylori-positive, stage IE, 64/29; H. pylori-negative, stage IE, 32/26.
†Total, stage IIE, 54/47; H. pylori-positive, stage IIE, 28/7; H. pylori-negative, stage IIE, 26/40.
‡Anthracycline based: CHOP, CEOP.
§Rituximab/anthracycline based: rituximab CHOP or rituximab CEOP.
¶Rituximab/non-anthracycline based: rituximab COP.
**Others: surgery+CHOP-like/rituximab-CHOP.
CEOP, cyclophosphamide, epirubicin (≥70 mg/m2), vincristine and prednisolone; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisolone; COP, cyclophosphamide, vincristine and prednisolone; ECOG, Eastern Cooperative Oncology Group; GCB, germinal center B-cell; HPE, H. pylori eradication; IPI, International Prognostic Index; LDH, lactate dehydrogenase; Non-GCB, non germial center B-cell; pCR, complete pathological remission; PD, progression; PR, partial remission; rituximab-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone; SD, stable disease; surgery, local resection of foci; TIL-Ts, tumor-infiltrating T-lymphocytes.